Dan Sherbenou, MD, PhD
Associate Professor, Medicine-Hematology

Photo
Medical School:
  • MD, Oregon Health & Science University School of Medicine (2009)
Graduate School :
  • PhD, Oregon Health And Science University (2009)
Undergraduate School:
  • BA, University of Colorado - Boulder (CO) (1999)
Internship:
  • University of Utah Medical Center Program (2010)
Residency:
  • University of Utah Medical Center Program, Internal Medicine (2012)
Fellowships:
  • University of California (San Francisco) Program, Medical Oncology (2015)
Languages: English
Department: Medicine-Hematology

Recognition & Awards

  • Young Investigator Award, Grand Multiple Myeloma Translational Initiative (2014)
    Translational development of novel antibody drug conjugates targeting multiple myeloma.

Research Interests

My lab is located in the blood cancer and bone marrow transplant program of the hematology division of the University of Colorado Anschutz Medical campus. Our research focus is in therapeutic optimization for multiple myeloma, especially for patients with drug resistant and advanced disease. In particular, we are interested in helping develop and apply new immunotherapies to myeloma, especially antibody-based therapies.

Teaching

  • Associate Professor (2021)
    School of Medicine, Medicine
    Multiple Myeloma

Publications

  • Walker ZJ, Idler BM, Davis LN, Stevens BM, VanWyngarden MJ, Ohlstrom D, Bearrows SC, Hammes A, Smith CA, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. Clin Cancer Res. 2021 Feb 1;27(3):819-830. PubMed PMID: 33109736
  • Davis LN, Sherbenou DW. Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma. Cancers (Basel). 2021 Apr 2;13(7). PubMed PMID: 33918370
  • Sherbenou D, Stalker M, Forsberg P, Mark TM. Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e630-e634. PubMed PMID: 33863694
  • Walker ZJ, Idler BM, Davis LN, Stevens BM, VanWyngarden MJ, Ohlstrom D, Bearrows SC, Hammes A, Smith CA, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. Clin Cancer Res. 2021 Feb 1;27(3):819-830. PubMed PMID: 33109736
  • Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG, Liu B. Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma. Clin Cancer Res. 2020 Nov 15;26(22):6028-6038. PubMed PMID: 32917735
  • Sharma P, Purev E, Haverkos B, Pollyea DA, Cherry E, Kamdar M, Mark T, Forsberg P, Sherbenou D, Hammes A, Rabinovitch R, Smith CA, Gutman JA. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Adv. 2020 May 26;4(10):2227-2235. PubMed PMID: 32442301
  • Walker ZJ, VanWyngarden MJ, Stevens BM, Abbott D, Hammes A, Langouët-Astrie C, Smith CA, Palmer BE, Forsberg PA, Mark TM, Jordan CT, Sherbenou DW. Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. Blood Adv. 2020 Apr 28;4(8):1628-1639. PubMed PMID: 32311014
  • Forsberg PA, Rossi AC, Boyer A, Tegnestam L, Pearse RN, Perry A, Pekle KA, Jayabalan D, Ely S, Boussi L, Sherbenou DW, Williams C, Allan JN, Coleman M, Niesvizky R, Mark TM. Phase II study of carfilzomib and dexamethasone (Kd) therapy for newly diagnosed multiple myeloma. Am J Hematol. 2019 Feb 10. [Epub ahead of print] PubMed PMID: 30740766
  • Forsberg PA, Hammes A, Abbott D, Sherbenou DW, Rossi A, Jayabalan D, Niesvizky R, Mark TM, Ely S. Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. Leuk Lymphoma. 2019 Jan 11;:1-3. [Epub ahead of print] PubMed PMID: 30632821
  • Harnoss JM, Le Thomas A, Shemorry A, Marsters SA, Lawrence DA, Lu M, Chen YA, Qing J, Totpal K, Kan D, Segal E, Merchant M, Reichelt M, Ackerly Wallweber H, Wang W, Clark K, Kaufman S, Beresini MH, Laing ST, Sandoval W, Lorenzo M, Wu J, Ly J, De Bruyn T, Heidersbach A, Haley B, Gogineni A, Weimer RM, Lee D, Braun MG, Rudolph J, VanWyngarden MJ, Sherbenou DW, Gomez-Bougie P, Amiot M, Acosta-Alvear D, Walter P, Ashkenazi A. Disruption of IRE1a through its kinase domain attenuates multiple myeloma. Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16420-16429. PubMed PMID: 31371506
  • Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019 Sep;6(9):e459-e469. PubMed PMID: 31327687
  • Forsberg PA, Rossi AC, Boyer A, Tegnestam L, Pearse RN, Perry A, Pekle KA, Jayabalan D, Ely S, Boussi L, Sherbenou DW, Williams C, Allan JN, Coleman M, Niesvizky R, Mark TM. Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. Am J Hematol. 2019 May;94(5):539-545. PubMed PMID: 30740766
  • Forsberg PA, Hammes A, Abbott D, Sherbenou DW, Rossi A, Jayabalan D, Niesvizky R, Mark TM, Ely S. Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. Leuk Lymphoma. 2019 Aug;60(8):2085-2087. PubMed PMID: 30632821
  • Lee NK, Zhang Y, Su Y, Bidlingmaier S, Sherbenou DW, Ha KD, Liu B. Cell-type specific potent Wnt signaling blockade by bispecific antibody. Sci Rep. 2018 Jan 15;8(1):766. PubMed PMID: 29335534
  • Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 Sep 6;3(17). [Epub ahead of print] PubMed PMID: 30185663
  • Sharma P, Pollyea DA, Smith CA, Purev E, Kamdar M, Haverkos B, Sherbenou D, Rabinovitch R, Hammes A, Gutman JA. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison. Biol Blood Marrow Transplant. 2018 Aug;24(8):1671-1677. PubMed PMID: 29684565
  • Lee NK, Zhang Y, Su Y, Bidlingmaier S, Sherbenou DW, Ha KD, Liu B. Cell-type specific potent Wnt signaling blockade by bispecific antibody. Sci Rep. 2018 Jan 15;8(1):766. PubMed PMID: 29335534
  • Sherbenou DW, Mark TM, Forsberg P. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future. Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):545-554. PubMed PMID: 28734795
  • Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Jun;23(6):930-937. PubMed PMID: 28285081
View All (19 Total) View Less

Professional Memberships

  • American Society of Hematology (ASH), Member
  • American Society of Clinical Oncology (ASCO), Member
  • Society for Immunotherapy of Cancer (SITC), Member

Practice Locations

UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus
1665 Aurora Court
3rd floor, Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-6400

UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Internal Medicine, Board Certification (2012)
  • Medical Oncology
  • Hematology, Board Certification (2012)
  • Colorado Medical License , License (2015)
Conditions & Treatments
  • Cancers - Myeloma
  • Cancers - Blood and Marrow Transplant
  • Cancers - Lymphoma
  • Cancers - Leukemia (Adult Acute)
  • Cancers - Leukemia (Adult Chronic)
  • Cancers
Clinical Interests
Multiple myeloma and related plasma cell disorders

Care Philosophy
I have devoted my professional life to understanding what makes cells become cancerous and how to turn that knowledge into the best possible treatments. I seek to empower my patients with knowledge about their disease and its treatments. For me, it is a privilege to provide cancer care and I strive to help patients realize their best possible quality of life.

Personal Interests
As an undergraduate at the University of Colorado, I started my scientific career focused on basic science research of cancer. In the laboratory of Dr. Min Han, I studied the Ras cell signaling pathway using the C. elegans model organism. In the MD/PhD program at Oregon Health & Science University, I focused on translational leukemia research. Under the mentorship of Drs. Brian Druker and Michael Deininger, I studied chronic myeloid leukemia. My thesis evaluated mechanisms of kinase inhibitor resistance in patients treated with imatinib (Gleevec). In oncology fellowship at University of California at San Francisco, I focused on the study of antibody-based therapeutics under the mentorship of Dr. Bin Liu. Antibody-drug conjugates (ADCs) are another rapidly growing approach to cancer treatment. With Dr. Liu, I conducted preclinical analyses of a novel ADC for multiple myeloma, with hope for this to soon lead to transition to the clinic. Now a faculty member at UC Denver in the Hematology division, I oversee a translational research laboratory focused on novel therapy development and optimization for multiple myeloma and care for patients with myeloma and related plasma cell disorders from Colorado and adjoining areas. In my spare time, I enjoy spending time with my wife and 2 young sons. I love the mountains and spending time outdoors, hiking, road biking, mountain biking and rock climbing.

Public Speaking
Yes

General Information

Medical Schools:
  • MD, Oregon Health & Science University School of Medicine (2009)
Graduate Schools:
  • PhD, Oregon Health And Science University (2009)
Undergraduate Schools:
  • BA, University of Colorado - Boulder (CO) (1999)
Internships:
  • University of Utah Medical Center Program (2010)
Residency Programs:
  • University of Utah Medical Center Program, Internal Medicine (2012)
Fellowships:
  • University of California (San Francisco) Program, Medical Oncology (2015)
Languages: English
Department: Medicine-Hematology
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;